These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 9005127)
1. [Role of biological indicators in the therapeutic decision in breast carcinoma]. Amadori D; Maltoni R Chir Ital; 1995; 47(4):15-22. PubMed ID: 9005127 [TBL] [Abstract][Full Text] [Related]
2. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550 [TBL] [Abstract][Full Text] [Related]
3. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
5. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886 [TBL] [Abstract][Full Text] [Related]
6. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590 [TBL] [Abstract][Full Text] [Related]
9. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229 [TBL] [Abstract][Full Text] [Related]
10. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands]. Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143 [TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732 [TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Newby JC; Johnston SR; Smith IE; Dowsett M Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855 [TBL] [Abstract][Full Text] [Related]
13. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer. Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189 [TBL] [Abstract][Full Text] [Related]
14. [Prognostic-predictive factors and therapeutic choices in invasive carcinoma of the breast]. Puglisi F; Di Loreto C; Beltrami CA Ann Ital Chir; 1999; 70(3):335-41. PubMed ID: 10466235 [TBL] [Abstract][Full Text] [Related]
15. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422 [TBL] [Abstract][Full Text] [Related]
16. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363 [TBL] [Abstract][Full Text] [Related]
17. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466 [TBL] [Abstract][Full Text] [Related]
18. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523 [TBL] [Abstract][Full Text] [Related]
19. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy. Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760 [TBL] [Abstract][Full Text] [Related]
20. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy. Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]